title: Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.
abstract: The search for melanoma biomarkers is crucial, as the incidence of melanoma continues to rise. We have previously demonstrated that serum CEACAM1 (sCEACAM1) is secreted from melanoma cells and correlates with disease progression in metastatic melanoma patients. Here, we have used a different cohort of melanoma patients with regional or metastatic disease (N = 49), treated with autologous vaccination. By monitoring sCEACAM1 in serum samples obtained prior to and after vaccination, we show that sCEACAM1 correlates with disease state, overall survival, and S100B. The trend of change in sCEACAM1 following vaccination (increase/decrease) inversely correlates with overall survival. DTH skin test is used to evaluate patients' anti-melanoma immune response and to predict response to vaccination. Importantly, sCEACAM1 had a stronger prognostic value than that of DTH, and when sCEACAM1 decreased following treatment, this was the dominant predictor of increased survival. Collectively, our results point out the relevance of sCEACAM1 in monitoring melanoma patients.
authors.affiliation: The Ella Institute for Treatment and Research of Melanoma and Skin Cancer, The Sheba Cancer Research Center, The Chaim Sheba Medical Center, Tel Hashomer 52621, Israel.
authors.forename: Sapoznik
authors.initials: S
authors.lastname: Sivan
authors.forename: Faranesh
authors.initials: F
authors.lastname: Suzan
authors.forename: Ortenberg
authors.initials: O
authors.lastname: Rona
authors.forename: Hamburger
authors.initials: H
authors.lastname: Tamar
authors.forename: Barak
authors.initials: B
authors.lastname: Vivian
authors.forename: Peretz
authors.initials: P
authors.lastname: Tamar
authors.forename: Schachter
authors.initials: S
authors.lastname: Jacob
authors.forename: Markel
authors.initials: M
authors.lastname: Gal
authors.forename: Lotem
authors.initials: L
authors.lastname: Michal
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood* / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage*; D015815:Cell Adhesion Molecules / Q000097:blood* / Q000276:immunology; D015331:Cohort Studies; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005720:Gamma Rays; D006801:Humans; D007279:Injections, Subcutaneous; D007557:Israel; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000276:immunology / Q000401:mortality / Q000628:therapy; D008875:Middle Aged; D009367:Neoplasm Staging; D009414:Nerve Growth Factors / Q000097:blood / Q000276:immunology; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood / Q000276:immunology; D012878:Skin Neoplasms / Q000097:blood* / Q000276:immunology / Q000401:mortality / Q000628:therapy; D012882:Skin Tests; D014182:Transplantation, Autologous; D014407:Tumor Cells, Cultured; D014613:Vaccines, Attenuated
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; C069847:CD66 antigens; D019496:Cancer Vaccines; D015815:Cell Adhesion Molecules; D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human; D014613:Vaccines, Attenuated